Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis [0.03%]
基于索非布韦的含或不含利巴韦林方案治疗丙型肝炎患者的安全性和有效性：系统评价和 Meta 分析
Shaimaa Elshafie,Rupal Trivedi-Kapoor,Mark Ebell
Shaimaa Elshafie
What is known and objective: Sofosbuvir (SOF) is a new and highly effective medication that dramatically improved hepatitis C virus (HCV) management. However, ribavirin (RBV) is still added to SOF-based medication regimen...
A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria [0.03%]
回顾性观察多粘菌素B治疗肝移植受者多重耐药革兰阴性细菌感染的效果及安全性分析
Ling-Ling Yu,Xiao-Ping Shi,Jun-Feng Huang et al.
Ling-Ling Yu et al.
What is known and objective: Only a few studies about polymyxin B (PMB) against multidrug-resistant gram-negative bacteria (MDR GNB) infection were conducted in liver transplantation recipients (LTRs). The purpose of this...
Observational Study
Journal of clinical pharmacy and therapeutics. 2022 Oct;47(10):1563-1569. DOI:10.1111/jcpt.13702 2022
Discoidin domain receptor 1 may be involved in biological barrier homeostasis [0.03%]
盘胞蛋白受体1可能参与生物屏障稳态调节
Xiaoli Li,Huiling Chen,Dekui Zhang
Xiaoli Li
What is known and objective: Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase involved in the pathological processes of several diseases, such as keloid formation, renal fibrosis, atherosclerosis, tumours,...
Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China [0.03%]
中国真实世界退行性心脏衰竭和高血压患者使用沙库必曲/缬沙坦疗效及安全性的回顾性研究
Chengchun Zuo,Xiaoye Li,Linlin Fan et al.
Chengchun Zuo et al.
What is known and objective: Hypertension (HP) is associated with heart failure (HF). Sacubitril/valsartan (sac/val) has been approved for primary HP by China Food and Drug Administration (CFDA) in June 2021. The present ...
Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system [0.03%]
依洛卓格导致血栓事件吗？一项FDA不良事件通报系统药物流行病学研究
Jing-Jing Jiang,Bin Zhao,Ji Li
Jing-Jing Jiang
What is known and objective: Eltrombopag is an orally bioavailable drug developed as a second-line treatment for immune thrombocytopenia. However, there are limited reports on thrombotic events related to eltrombopag use....
Tall man lettering application in medication information systems as a quality and safety strategy in hospital organization [0.03%]
应用于医疗机构中的药品信息系统的高个子字母书写作为医院组织的质量与安全策略
Ruben Iglesias Gomez,Isabel Font Noguera,Marta Correa Ballester et al.
Ruben Iglesias Gomez et al.
What is known and objective: The technique of highlighted capital letters, Tall Man lettering, is a tool that allows differentiating the names of similar drugs in a way that contributes to reduce medication errors related...
Observational Study
Journal of clinical pharmacy and therapeutics. 2022 Oct;47(10):1570-1575. DOI:10.1111/jcpt.13703 2022
Validation of the Augmented Renal Clearance in Trauma Intensive Care scoring system for augmented renal clearance prediction in a trauma subgroup of a mixed ICU population [0.03%]
验证创伤重症监护室患者augmented renal clearance增高的预测评分系统在混合ICU人群中某一亚组的有效性
Caren Jabamikos,Yi Tong Fang,Kim-Dan Nguyen et al.
Caren Jabamikos et al.
What is known and objective: Augmented renal clearance is prevalent in trauma patients and leads to subtherapeutic levels of renally eliminated medications with potentially unfavourable clinical outcomes. The Augmented Re...
Observational Study
Journal of clinical pharmacy and therapeutics. 2022 Oct;47(10):1517-1524. DOI:10.1111/jcpt.13695 2022
Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance [0.03%]
用于肾功能增强患者高剂量替考拉宁治疗的谷浓度分布及其安全性
Sasa Hu,Taotao Wang,Haisheng You et al.
Sasa Hu et al.
What is known and objective: There are few reports on the distribution of the plasma trough concentration (Cmin ) of teicoplanin in patients with augmented renal clearance (ARC) and on the safety of a high-dose regimen (H...
Addition of roxadustat to erythropoiesis-stimulating agent (ESA) effectively corrects ESA-hyporesponsive anaemia in patients on peritoneal dialysis [0.03%]
罗沙司他辅助促红细胞生成素疗效不佳的腹膜透析患者纠正贫血效果良好
Shuqi Dai,Yun Chen,Chuanming Hao et al.
Shuqi Dai et al.
What is known and objective: Erythropoiesis-stimulating agent (ESA) hyporesponsiveness is an important cause for the undertreatment of anaemia. A decrease in haemoglobin (Hb) levels was observed during the initial stage o...
SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities [0.03%]
在具有显著合并症的种族多样化的患者队列中评估SARS-CoV-2单克隆抗体治疗COVID-19的效果：巴利西韦单药与巴利西韦和埃特司维单抗联合用药的疗效比较
Lea M Monday,Indira Brar,George Alangaden et al.
Lea M Monday et al.
What is known and objective: Anti-spike monoclonal antibodies (MAB) including bamlanivimab (BAM) and bamlanivimab/etesevimab (BAM/E) have shown reduced hospitalization rates for non-severe coronavirus disease 2019 (COVID-...